Navigation Links
PharmAthene Reports First Quarter 2011 Financial and Operating Results
Date:5/11/2011

er the Company's SparVax™ program and the completion of patient dosing in the Phase I Valortim® dose escalation clinical trial, partially offset by the decrease in development expenses related to the Protexia® bioscavenger program, which was completed in 2010.

General and administrative expenses for the Company were $4.9 million and $5.3 million for the quarters ended March 31, 2011 and 2010, respectively.  The decrease in general and administrative expense during the most recent period resulted from cost reductions implemented during 2010 and a reduction in bad debt expense, partially offset by an increase in legal costs associated with the trial in the case against SIGA.

For the first quarter of 2011 PharmAthene's net loss attributable to common shareholders was $2.1 million, or $0.04 per share, compared to $7.9 million, or $0.28 per share, in the same period of 2010.  The year-over-year decrease in net loss includes the impact of the change in fair value of the Company's derivative instruments, which was $2.5 million for the three months ended March 31, 2011 compared to $0.3 million for the three months ended March 31, 2010. The decrease in fair value, which became a source of other income, was primarily associated with a decrease in PharmAthene's stock price from December 31, 2010 to March 31, 2011.

As of March 31, 2011, the Company had cash and cash equivalents, short-term investments, and net U.S. government accounts receivables and other receivables, including unbilled receivables, totaling approximately $18.7 million compared to $21.6 million at December 31, 2010.  The decrease at March 31, 2011 was primarily attributable to the net impact of cash used to fund operations.

"We continued to make steady progress in the first quarter of 2011 and achieved important program milestones," remarked Eric I. Richman, President and Chief Executive Officer. "We achieved several technical milestones with respect
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
2. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
3. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
4. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
5. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
6. PharmAthene Announces Pricing of $15 Million Public Offering
7. PharmAthene Announces Proposed Common Stock Offering
8. PharmAthene Announces $3.9 Million Registered Direct Offering
9. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
10. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
11. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... September 20, 2014 MediVet America ... perform a groundbreaking surgery at the specialized Wolvega Horse ... superficial digital flexor tendon was ruptured 90% and her ... injury is a death sentence for a horse. , ... stem cell treatments . This revolutionary regenerative option ...
(Date:9/19/2014)... Scientists at NYU Langone Medical Center have found ... the process for turning adult cells into so-called pluripotent ... C. Using the new technique in mice, the researchers ... skin cells by more than 20-fold compared with the ... reliable, and thus should generally accelerate research aimed at ...
(Date:9/19/2014)... 2014  An entire month is dedicated to one ... Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease affecting ... atrophy, weakness, and foot and hand deformities. CMT affects ... CMT is a progressive disease, and over time patients ... devices such as leg braces, wheelchairs and scooters to ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. ... the development of high-value and difficult to manufacture proteins ... presenting at the 21 st Annual NewsMakers in ... . Bertrand Liang , chief executive officer ... development programs and business strategy on Friday, September 26, ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Pfenex to Present at Upcoming Industry Conference on September 26 2
... Systems Medicine, LLC (SM),a wholly-owned subsidiary of Cell ... they have entered into a Cooperative Research,and Development ... the National Institutes of Health (NIH). The goal ... the treatment of patients with cancer --,specifically, human ...
... 21 Medpace,Inc., a leading global full-service ... the acquisition of Monax s.r.o., a regional,contract ... This move strengthens the Medpace presence in ... full service clinical research management,within the Czech ...
... PLSG Invests $450,000 in Three Companies, PITTSBURGH, ... the private/public partnership putting the region,s life,sciences industry ... the PLSG has,invested a total of $450,000 in ... ThermalTherapeutics Systems. "PLSG is committed to identifying ...
Cached Biology Technology:Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway 2Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway 3Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway 4Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway 5Medpace Strengthens Presence in Central Europe 2The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio 2The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio 3
(Date:9/19/2014)... University of Oklahoma biology professor will study the unique ... that could eventually benefit people,s health. The OU ... the energy required to produce the signals used to ... electric signals at a rate of 500-600 discharges a ... for the electric fish are extreme, but necessary for ...
(Date:9/19/2014)... the sake of fairness per se but in order ... Frans de Waal, PhD, and Sarah Brosnan, PhD, co-authors ... is defined as a negative reaction to unequal outcomes. ... , Their conclusion comes after the co-authors reviewed more ... it is the evolution of forestalling partner dissatisfaction with ...
(Date:9/19/2014)... , Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: ... company focused on the growing m-commerce market, updates the "Wocket in ... in the lightweight and light middleweight weight classes, Vinny Pazienza ... was announced that Game of Thrones actor Ciaran ... with Children star Katey Sagal have been cast ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3
... a faulty protein wreaks havoc in cells and causes ... at a wayward gene. Now scientists are learning that ... is perfectly normal. The diseases can be caused when ... executed properly, leading to a lethal buildup of malformed ...
... sticking power, marine mussels are hard to beat. They ... sustaining their tenacious bonds in saltwater, including turbulent tidal ... bivalves achieve this amazing feat. , In a paper ... by the Proceedings of the National Academy of Sciences, ...
... nerve cells in adult brains live or die depends on ... mature neurons. Neuroscientists at the Salk Institute for Biological Studies ... to successfully jump into the fray and hook up with ... forthcoming issue of Nature, researchers in the lab of Fred ...
Cached Biology News:'Sticky' mice lead to discovery of new cause of neurodegenerative disease 2'Sticky' mice lead to discovery of new cause of neurodegenerative disease 3'Sticky' mice lead to discovery of new cause of neurodegenerative disease 4Study reveals details of mussels' tenacious bonds 2Life and death in the hippocampus: what young neurons need to survive 2Life and death in the hippocampus: what young neurons need to survive 3
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
HyPro 20 system for slide hybridization. 20 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Biology Products: